Last updated: September 9, 2026
Cetirizine hydrochloride/pseudoephedrine hydrochloride is a mature oral allergy and nasal-congestion combination sold primarily as Zyrtec-D and generic equivalents. Its commercial value is constrained by generic competition, pseudoephedrine purchase restrictions, and seasonal demand. The product has no material remaining patent or regulatory exclusivity barrier in the United States. Financial performance depends more on retail distribution, private-label pricing, retailer access, and respiratory-season intensity than on innovation or patent protection.
What is cetirizine hydrochloride and pseudoephedrine hydrochloride?
The combination treats allergic rhinitis with two pharmacologic components:
| Component |
Function |
Common extended-release strength |
| Cetirizine hydrochloride |
Second-generation H1 antihistamine |
5 mg |
| Pseudoephedrine hydrochloride |
Nasal decongestant |
120 mg |
| Combined product |
Allergy symptoms plus nasal congestion |
One tablet every 12 hours |
The U.S. reference product is Zyrtec-D 12 Hour, an extended-release tablet marketed by Kenvue following Johnson & Johnson’s consumer-health separation. Cetirizine reduces sneezing, rhinorrhea and itching. Pseudoephedrine reduces nasal congestion through systemic sympathomimetic activity.
The combination differs from ordinary cetirizine products because cetirizine alone does not provide meaningful decongestant activity. It also differs from intranasal corticosteroids, which are generally preferred for persistent allergic rhinitis but do not provide the same immediate systemic decongestant effect.
What is the FDA regulatory status of cetirizine/pseudoephedrine?
The U.S. product was approved under NDA 020786 as an extended-release combination. The product moved into the mature OTC market after the individual active ingredients had established safety and efficacy records. Cetirizine became available over the counter in the United States in 2007, while pseudoephedrine products remained subject to controlled retail-access requirements because of diversion concerns.
The combination is sold under the OTC monograph framework and approved product labeling. Its commercial status is distinct from ordinary unrestricted shelf OTC products because federal law requires pseudoephedrine products to remain behind the pharmacy counter or in a controlled-access area.
The FDA’s 2023 proposal to remove oral phenylephrine as an effective OTC nasal decongestant may support relative demand for pseudoephedrine-containing products. The proposal did not remove pseudoephedrine from the market, but it increased scrutiny of competing oral decongestant products (FDA, 2023).
What is the Orange Book status of Zyrtec-D?
Zyrtec-D has no commercially meaningful period of remaining U.S. patent exclusivity. The relevant protection historically covered the active ingredients, the combination and the extended-release dosage form. Those rights have expired or are no longer sufficient to prevent generic competition.
| Protection category |
Commercial position |
| Cetirizine active-ingredient patents |
Expired |
| Pseudoephedrine active-ingredient patents |
Expired |
| Combination patents |
Expired or commercially non-blocking |
| Extended-release formulation patents |
Expired or commercially non-blocking |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Current practical barrier |
Retail controls and manufacturing complexity, not patent rights |
The Orange Book remains relevant for identifying listed patents associated with the approved NDA and for tracking any historical patent certifications. It does not create a current market monopoly for the combination. Generic manufacturers can compete through ANDA approvals, subject to formulation, bioequivalence and labeling requirements.
When does cetirizine/pseudoephedrine lose exclusivity?
The product has already lost meaningful exclusivity. The main U.S. commercial transition occurred after:
- Cetirizine’s prescription-to-OTC switch in 2007.
- Expansion of generic cetirizine products.
- Generic development of cetirizine/pseudoephedrine extended-release tablets.
- Expiration of formulation and combination patent positions.
The product’s current economics are therefore those of a mature branded OTC medicine. The brand can preserve a price premium through consumer recognition, retailer placement and perceived quality, but it cannot rely on patent exclusion.
How many patents cover cetirizine and pseudoephedrine?
The historical patent estate included multiple patent families, but the number of historical documents is less relevant than whether an enforceable patent currently blocks generic entry. The active ingredients are old, widely manufactured compounds. The principal technical protection related to the combination’s extended-release delivery profile and tablet design.
No active U.S. patent position is known to create a material barrier to generic competition for the standard 5 mg/120 mg, 12-hour product. Patent risk is therefore low relative to products with active composition-of-matter, crystal-form or device patents.
What formulations are protected?
Historically relevant formulation elements included:
- Extended-release pseudoephedrine delivery.
- Immediate-release or controlled-release cetirizine components.
- Bilayer or multilayer tablet structures.
- Polymer matrices controlling pseudoephedrine release.
- Tablet coating and dissolution profiles.
- Stability protection for the combined dosage form.
These elements can still create regulatory and manufacturing work, but they do not provide durable exclusivity when the relevant patents have expired. A generic applicant must demonstrate bioequivalence to the reference product, including release behavior and pharmacokinetic performance.
Are there Paragraph IV challenges to Zyrtec-D?
Paragraph IV litigation is not a major current market driver for this product. Paragraph IV certifications were more relevant during the original generic-entry phase, when manufacturers challenged listed patents before expiration. With the principal patent estate mature or expired, the market has moved from patent litigation to commodity competition.
A modern generic launch could proceed through one of three routes:
| Launch route |
Commercial effect |
| Paragraph III certification |
Entry after listed patent expiration |
| Paragraph IV certification |
Earlier entry if patents are challenged and invalidated or not enforced |
| Patent-expired ANDA pathway |
Direct generic entry with limited litigation exposure |
The principal risks for generic applicants are now bioequivalence, controlled-substance handling, production consistency and retail distribution rather than patent validity.
What patent litigation affects cetirizine/pseudoephedrine?
No current litigation is known to materially restrict U.S. access to the standard cetirizine/pseudoephedrine combination. Historical litigation would have centered on extended-release formulation claims, generic ANDA filings and Orange Book patent certifications.
The litigation profile is lower than for newer extended-release products because:
- The active ingredients are long established.
- The reference product has been commercially available for decades.
- Multiple suppliers and generic channels exist.
- No active composition-of-matter patent protects the combination.
- Generic substitution is accepted by pharmacists and retailers.
Litigation risk can still arise from manufacturing-process patents, trade dress, trademarks or product-specific release technologies. Those rights are narrower than patent rights that block the entire active ingredient.
What is the competitive landscape for Zyrtec-D?
The market has four primary competitive groups.
Cetirizine-only products
Products such as generic cetirizine and Zyrtec address allergy symptoms without pseudoephedrine. They are lower-cost substitutes when congestion is not the dominant symptom. Their broad retail availability reduces the need for the combination product.
Other antihistamine-decongestant combinations
Claritin-D combines loratadine and pseudoephedrine. Allegra-D combines fexofenadine and pseudoephedrine. These products compete directly on duration, perceived sedation, symptom control and brand familiarity.
| Product |
Antihistamine |
Decongestant |
Main competitive position |
| Zyrtec-D |
Cetirizine |
Pseudoephedrine |
Strong allergy recognition, possible sedation concerns |
| Claritin-D |
Loratadine |
Pseudoephedrine |
Low-sedation positioning |
| Allegra-D |
Fexofenadine |
Pseudoephedrine |
Low-sedation and nonprescription allergy positioning |
| Generic equivalents |
Varies |
Pseudoephedrine |
Lowest price and retailer contracting |
Intranasal products
Fluticasone, triamcinolone and other intranasal corticosteroids compete for allergic-rhinitis spending. Intranasal products have stronger clinical positioning for persistent nasal inflammation but do not offer the same immediate oral decongestant effect.
Oral phenylephrine products
Oral phenylephrine products historically occupied broad retail space. FDA’s assessment that the oral formulation is ineffective at the recommended OTC dose threatens that segment and may redirect some consumers toward pseudoephedrine products, although purchase restrictions limit the size of the benefit (FDA, 2023).
How do pseudoephedrine restrictions affect sales?
Pseudoephedrine is a regulated precursor under the Combat Methamphetamine Epidemic Act of 2005. U.S. purchasers generally must provide identification, and retailers must maintain purchase records. Federal sales limits are 3.6 grams per day and 9 grams during a 30-day period for nonmail transactions, with additional state-level restrictions possible (U.S. Drug Enforcement Administration, 2024).
These requirements affect the combination in four ways:
- They reduce impulse purchases.
- They restrict shelf visibility.
- They increase pharmacy labor and compliance costs.
- They make retailer execution more important than ordinary OTC advertising.
The controls also reduce direct substitution from unrestricted antihistamine products. Consumers seeking congestion relief may choose intranasal sprays or non-pseudoephedrine products to avoid pharmacy-counter transactions.
What is the financial trajectory of cetirizine/pseudoephedrine?
The financial trajectory is mature-to-declining in unit economics, with periodic seasonal rebounds. Revenue is not generally disclosed separately for Zyrtec-D or the active-ingredient combination. Kenvue reports broader consumer-health categories and brand portfolios rather than product-level Zyrtec-D sales, limiting precise public revenue attribution (Kenvue, 2024).
The trajectory has four phases:
| Phase |
Financial characteristics |
| Prescription and early branded period |
High brand value and limited direct substitution |
| OTC conversion |
Larger consumer reach and increased volume |
| Generic expansion |
Price compression and retailer private-label substitution |
| Mature market |
Stable seasonal demand, lower margins, limited innovation |
The product can remain profitable because the active ingredients are inexpensive and manufacturing is established. Profitability is pressured by:
- Generic price competition.
- Retailer private-label programs.
- Pharmacy-counter access constraints.
- Promotional spending.
- Seasonal inventory volatility.
- Reduced consumer use of systemic decongestants.
- Competition from intranasal corticosteroids.
Brand Zyrtec-D is more likely to preserve dollar sales than unit share because of brand recognition and premium pricing. Generic products are more likely to capture volume, especially through pharmacy chains, mass merchants and online channels where pseudoephedrine controls can still be operationally managed.
What revenue exposure does Kenvue have to Zyrtec-D?
Zyrtec-D is strategically relevant to Kenvue’s self-care portfolio but is unlikely to be a separately material revenue driver at the consolidated-company level. Kenvue’s reporting combines major consumer-health brands and does not normally disclose Zyrtec-D revenue as an individual line item.
The financial exposure is therefore best assessed through:
- Seasonal respiratory and allergy performance.
- U.S. antihistamine and decongestant market share.
- Brand versus private-label pricing.
- Retail distribution and pharmacy-counter availability.
- Gross-margin movement in the self-care segment.
The brand’s downside is limited by its mature cost base but also has limited upside because patent-based price expansion is unavailable.
How strong is the patent estate for cetirizine/pseudoephedrine?
The patent estate is weak as a current exclusivity asset and moderately relevant as a formulation-compliance asset.
| Factor |
Assessment |
| Composition-of-matter protection |
None of practical current value |
| Formulation protection |
Historically relevant, now largely expired |
| Method-of-use protection |
Limited commercial importance |
| Trademark protection |
More important than patent protection |
| Generic-entry risk |
High |
| Biosimilar risk |
Not applicable |
| Manufacturing barrier |
Moderate |
| Regulatory barrier |
Moderate because of extended-release bioequivalence |
Trademark, packaging and retailer relationships now protect more value than patents. The brand can differentiate on consumer trust, but generic substitution remains straightforward.
Is there biosimilar risk for cetirizine/pseudoephedrine?
No. Biosimilars apply to biological products, not small-molecule oral tablets. The relevant competitive threat is generic substitution, not biosimilar entry.
Generic manufacturers do not need to reproduce a biologic manufacturing process. They must meet applicable quality, dissolution, stability and bioequivalence requirements for the extended-release tablet.
Are there licensing deals for cetirizine/pseudoephedrine?
The commercial history involved development and commercialization relationships around cetirizine, including the broader originator relationship between UCB and Johnson & Johnson’s consumer-health operations. Current economics are dominated by branded commercialization and generic supply rather than a newly negotiated product-specific licensing structure.
No major current licensing transaction is known to materially change the competitive position of the standard combination. Contract manufacturing, private-label supply and distributor arrangements are more commercially relevant than patent licensing.
What generic launch scenarios exist?
The most likely scenarios are:
Continued branded-generic coexistence
Zyrtec-D remains available at a premium while store brands capture price-sensitive demand. This is the base case.
Retailer-led private-label expansion
Large chains increase shelf and pharmacy-counter placement for generic extended-release tablets. This would pressure brand volume and gross margin.
Seasonal demand spike
Severe allergy seasons, respiratory infections or congestion-heavy consumer demand can raise short-term volume. Such increases are cyclical rather than structural.
Shift toward non-pseudoephedrine alternatives
Consumers may move to intranasal corticosteroids, saline products or antihistamine-only products because of purchase friction and concerns about systemic decongestant effects.
Reduced oral phenylephrine competition
If FDA action removes or materially limits oral phenylephrine products, pseudoephedrine combinations may gain some substitution demand. The effect is likely to be constrained by controlled retail access.
What manufacturing and geographic barriers apply?
The active ingredients are globally available and chemically uncomplicated. Manufacturing barriers arise from:
- Extended-release tablet engineering.
- Control of dissolution profiles.
- Stability of the combination.
- Consistent dose uniformity.
- Controlled handling and documentation of pseudoephedrine.
- U.S. pharmacy-counter distribution requirements.
The United States is the most commercially important controlled-access market. Other countries regulate pseudoephedrine differently, and product availability varies by national OTC classification, pack size and combination-product rules. A formulation approved in one jurisdiction may require separate regulatory review elsewhere.
Key Takeaways
- Cetirizine/pseudoephedrine is a mature, genericized oral allergy and decongestant combination.
- Zyrtec-D’s commercial strength comes from brand recognition, not active patent exclusivity.
- Generic-entry risk is high, while biosimilar risk is irrelevant.
- The principal technical barrier is extended-release bioequivalence, not composition-of-matter protection.
- Pseudoephedrine purchase controls restrict impulse demand and increase pharmacy execution costs.
- Revenue is seasonal and not separately disclosed by Kenvue.
- Generic and private-label products are likely to capture additional unit share over time.
- FDA scrutiny of oral phenylephrine could provide limited substitution support for pseudoephedrine products.
- The most important competitive assets are trademarks, retail distribution, supply reliability and consumer recognition.
FAQs
Is Zyrtec-D still patent protected?
No material active U.S. patent exclusivity is understood to block generic competition for the standard cetirizine 5 mg/pseudoephedrine 120 mg extended-release product.
Is cetirizine/pseudoephedrine prescription-only?
In the United States, it is generally sold without a prescription but must be obtained through controlled retail access because it contains pseudoephedrine.
Which is stronger, Zyrtec-D or Claritin-D?
Neither is universally stronger. Zyrtec-D contains cetirizine, while Claritin-D contains loratadine. Both use pseudoephedrine for congestion, and individual response, sedation sensitivity and allergy profile determine preference.
Can a company launch generic cetirizine/pseudoephedrine without challenging a patent?
Yes. With the relevant patent estate expired or non-blocking, an applicant can pursue the applicable ANDA pathway without relying on a commercially significant Paragraph IV challenge.
What is the largest long-term threat to Zyrtec-D sales?
The main threat is substitution by low-priced generics, antihistamine-only products and intranasal therapies, reinforced by the purchase restrictions and operational friction associated with pseudoephedrine.
References
- U.S. Food and Drug Administration. (2023). FDA proposes removing oral phenylephrine from OTC monograph. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov
- Kenvue Inc. (2024). Annual report. https://www.kenvue.com
- U.S. Drug Enforcement Administration. (2024). Pseudoephedrine: Federal retail sales limits and requirements. https://www.dea.gov
- U.S. Food and Drug Administration. (2007). FDA approves over-the-counter status for Zyrtec. https://www.fda.gov
